Pharmacological Profile and Clinical Utility of Lamotrigine in Mood Disorders

Bipolar Psychopharmacotherapy: Caring for the Patient: Second Edition

Volumn , Issue , 2011, Pages 45-60

  van der Loos, Marc L M ^a   Calabrese, Joseph R ^b   Nolen, Willem A ^c   Muzina, David J ^d  

^a Isala Klinieken ^*  (Netherlands)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bipolar Depression; Drug Interactions; Lamotrigine Use in Women; Pharmacodynamics; Pharmacokinetics; Pharmacological Profile and Clinical Utility of Lamotrigine in Mood Disorders

Indexed keywords

EID: 84885519966     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470975114.ch4     Document Type: Chapter

References (67)

1. Anderson, G.D., Yau, M.K., Gidal, B.E. et al. (1996) Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin. Pharmacol. Ther., 60, 145-156.
2. Barbosa, L., Berk, M., and Vorster, M. (2003) A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J. Clin. Psychiatry, 64, 403-407.
3. Bowden, C.L. (2003) Acute and maintenance treatment with mood stabilizers. Int. J. Neuropsychopharmacol., 6, 269-275.
4. Bowden, C.L., Calabrese, J.R., Sachs, G. et al. (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry, 60, 392-400.
5. Brown, E.B., McElroy, S.L., Keck, P.E. et al. (2006) Olanzapine/Fluoxetine Combination versus Lamotrigine in the treatment of bipolar I depression. J. Clin. Psychiatry, 67, 1025-1033.
6. Calabrese, J.R., Bowden, C.L., McElroy, S.L. et al. (1999a) Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am. J. Psychiatry, 156, 1019-1023.
7. Calabrese, J.R., Bowden, C.L., Sachs, G.S. et al. (1999b) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 study group. J. Clin. Psychiatry, 60, 79-88.
8. Calabrese, J.R., Bowden, C.L., Sachs, G. et al. (2003a) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry, 64, 1013-1024.
9. Calabrese, J.R., Hirschfeld, R.M., Reed, M. et al. (2003b) Impact of bipolar disorder on a U.S. community sample. J. Clin. Psychiatry, 64, 425-432.
10. Calabrese, J.R., Fatemi, S.H., and Woyshville, M.J. (1996) Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am. J. Psychiatry, 153, 1236.
11. Calabrese, J.R., Huffman, R.F., White, R.L. et al. (2007) Additional clinical trial data and a retrospective pooled analysis of response rates across all randomized trials conducted by GSK. Bipolar Disord., 8 (Suppl. 1), 323-333.
12. Calabrese, J.R., Sullivan, J.R., Bowden, C.L. et al. (2002) Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J. Clin. Psychiatry, 63, 1012-1019.
13. Calabrese, J.R., Suppes, T., Bowden, C.L. et al., Lamictal 614 Study Group (2000) A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J. Clin. Psychiatry, 61, 841-850.
14. Calabrese, J.R., Vieta, E., and Shelton, M.D. (2003c) Latest maintenance data on lamotrigine in bipolar disorder. Eur. Neuropsychopharmacol., 13 (Suppl. 2), S57-S66.
15. Chen, C., Veronese, L., and Yin, Y. (2000) The effects of lamotrigine on the pharmacokinetics of lithium. Br. J. Clin. Pharmacol., 50, 193-195.
16. Choi, H. and Morrell, M.J. (2003) Review of lamotrigine and its clinical applications in epilepsy. Exp. Opin. Pharmacother., 4, 243-251.
17. Cohen, A.F., Ashby, L., Crowley, D. et al. (1985) Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br. J. Clin. Pharmacol., 20, 619-629.
18. Cohen, A.F., Land, G.S., Breimer, D.D. et al. (1987) Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther., 42, 535-541.
19. Cunnington, M. and Tennis, P., The International Lamotrigine Pregnancy Registry Scientific Advisory
20. Committee (2005) Lamotrigine and the risk of malformations in pregnancy. Neurology, 64, 955-960.
21. Fitton, A. and Goa, K.L. (1995) Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs, 50, 691-713.
22. Frye, M.A., Ketter, T.A., Kimbrell, T.A. et al. (2000) A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol., 20, 607-614.
23. Garnett, W.R. (1997) Lamotrigine: pharmacokinetics. J. Child Neurol., 12 (Suppl. 1), S10-S15.
24. Geddes, J.R., Calabrese, J.R., and Goodwin, G.M. (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br. J. Psychiatry, 194, 4-9.
25. Gilman, J.T. (1995) Lamotrigine: an antiepileptic agent for the treatment of partial seizures. Ann. Pharmacother., 29, 144-151.
26. Ginsberg, L., Sachs, G., and Ketter, T. (2003) Poster presented at the American Psychiatric Association 2003 Annual Meeting, San Francisco, CA, pp. 173-174.
27. Goa, K.L., Ross, S.R., and Chrisp, P. (1993) Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs, 46, 152-176.
28. Goldberg, J.F., Bowden, C.L., Calabrese, J.R. et al. (2008) Six-month prospective life charting of mood symptoms with lamotrigine monotherapy versus placebo in rapid cycling bipolar disorder. Biol. Psychiatry, 63, 125-130.
29. Goldberg, J.F., Calabrese, J.R., Saville, B.R. et al. (2009) Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. J. Clin. Psychiatry, 70, 1273-1280.
30. Goldsmith, D.R., Wagstaff, A.J., Ibbotson, T. et al. (2003) Lamotrigine: a review of its use in bipolar disorder. Drugs, 63, 2029-2050.
31. Hachad, H., Ragueneau-Majlessi, I., and Levy, R.H. (2002) New antiepileptic drugs: review on drug interactions. Ther. Drug Monit., 24, 91-103.
32. Hirschfeld, R.M., Calabrese, J.R., Weissman, M.M. et al. (2003) Screening for bipolar disorder in the community. J. Clin. Psychiatry, 64, 53-59.
33. Holmes, L.B., Baldwin, E.J., Smith, C.R. et al. (2008) Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology, 70, 2152-2158.
34. Ichim, L., Berk, M., and Brook, S. (2000) Lamotrigine compared with lithium in mania: a doubleblind randomized controlled trial. Ann. Clin. Psychiatry, 12, 5-10.
35. Judd, L.L., Akiskal, H.S., Schettler, P.J. et al. (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry, 59, 530-537.
36. Kupka, R.W., Luckenbaugh, D.A., Post, R.M. et al. (2005) Comparison of rapid-cycling and nonrapid- cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am. J. Psychiatry, 162, 1273-1280.
37. Ketter, T.A., Greist, J.H., Graham, J.A. et al. (2006) The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar i disorder: a randomized trial. J. Clin. Psychiatry, 67, 400-406.
38. Kusumakar, V. and Yatham, L.N. (1997) An open study of lamotrigine in refractory bipolar depression. Psychiatry Res., 72, 145-148.
39. Leach, M.J., Baxter, M.G., and Critchley, M.A. (1991) Neurochemical and behavioral aspects of lamotrigine. Epilepsia, 32 (Suppl. 2), S4-S8.
40. Leach, M.J., Marden, C.M., and Miller, A.A. (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia, 27, 490-497.
41. Li, X., Ketter, T.A., and Frye, M.A. (2002) Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J. Affect. Disord., 69, 1-14.
42. Matsuo, F., Bergen, D., Faught, E. et al., U.S. Lamotrigine Protocol 0.5 Clinical Trial Group (1993) Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology, 43, 2284-2291.
43. Messenheimer, J.A. (2002) Poster presented at the American Academy of Neurology Annual Meeting Denver, CO.
44. Mikati, M.A., Schachter, S.C., Schomer, D.L. et al. (1989) Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. Clin. Neuropharmacol., 12, 312-321.
45. Normann, C., Hummel, B., Scharer, L.O. et al. (2002) Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J. Clin. Psychiatry, 63, 337-344.
46. Ohman, I., Vitols, S., and Tomson, T. (2000) Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia, 41, 709-713.
47. Pennell, P.B. (2003) Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology, 61, S35-S42.
48. Post, R.M., Denicoff, K.D., and Leverich, G.S. (2002) Presentations of depression in bipolar illness. Clin. Neurosci. Res., 2, 142-157.
49. Rambeck, B. and Wolf, P. (1993) Lamotrigine clinical pharmacokinetics. Clin. Pharmacokinet., 25, 433-443.
50. Ramsay, R.E., Pellock, J.M., Garnett, W.R. et al. (1991) Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res., 10, 191-200.
51. Regeer, E.J., ten Have, M., Rosso, M.L. et al. (2004) Prevalence of bipolar disorder in the general population: a reappraisal study of the Netherlands mental health survey and incidence study. Acta Psychiatr. Scand., 110, 5374-5382.
52. Rzany, B., Mockenhaupt, M., Baur, S. et al. (1996) Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J. Clin. Epidemiol., 49, 769-773.
53. Shiah, I.S., Yatham, L.N., Lam, R.W. et al. (1998) Effects of lamotrigine on the 5-HT1A receptor function in healthy human males. J. Affect. Disord., 49, 157-162.
54. Sidhu, J., Job, S., Singh, S. et al. (2006) The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br. J. Clin. Pharmacol., 61, 191-199.
55. Smith, D., Baker, G., Davies, G. et al. (1993a) Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia, 34, 312-322.
56. Smith, D., Chadwick, D., Baker, G. et al. (1993b) Seizure severity and the quality of life. Epilepsia, 34 (Suppl. 5), S31-S35.
57. Tran, T.A., Leppik, I.E., Blesi, K. et al. (2002) Lamotrigine clearance during pregnancy. Neurology, 59, 251-255.
58. Van der Loos, M.L., Mulder, P.G., Hartong, E.G. et al. (2009) Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J. Clin. Psychiatry, 70, 223-231.
59. Van der Loos, M.L., Mulder, P., Hartong, E.G. et al. (2010 Sep.) Efficacy and safety of two treatment algorithms in bipolar depression: lithium plus lamotrigine versus lithium plus placebo both followed by addition of paroxetine in non-responders. Acta Psychiatr. Scand., 122(3), 246-254.
60. Vinod, K.Y. and Subhash, M.N. (2002) Lamotrigine induced selective changes in 5-HT(1A) receptor mediated response in rat brain. Neurochem. Int., 40, 315-319.
61. Walden, J., Hesslinger, B., van Calker, D. et al. (1996) Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry, 29, 193-195.
62. Weisler, R., Risner, M., Ascher, J. et al. (1994) Poster presented at the American Psychiatric Association 1994 Annual Meeting, Philadelphia, PA.
63. Weissman, M.M., Bland, R.C., Canino, G.J. et al. (1996) Cross-national epidemiology of major depression and bipolar disorder. J. Am. Med. Assoc., 276, 293-299.
64. Wong, I.C., Mawer, G.E., and Sander, J.W. (1999) Factors influencing the incidence of lamotriginerelated skin rash. Ann. Pharmacother., 33, 1037-1042.
65. Xie, X. and Hagan, R.M. (1998) Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology, 38, 119-130.
66. Xie, X., Lancaster, B., Peakman, T. et al. (1995) Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones. Pflugers Arch., 430, 437-446.
67. Yuen, A.W., Land, G., Weatherley, B.C. et al. (1992) Sodium valproate acutely inhibits lamotrigine metabolism. Br. J. Clin. Pharmacol., 33, 511-513.